In Silico ADMET and Drug-Likeness Evaluation of Withaferin A from Withania somnifera for Potential Application in Alzheimer’s Disease

By Bhavesh Girdhar Mali, Tushar Narendra Chaudhari, Neha Hiralal Deore, Nilesh P. Salunkhe*, Vaidhali D. Shewale

NTVS Institute of Pharmacy, Nandurbar (MS), India

Published: April 2026 | DOI: 10.5281/zenodo.19849845 | Download PDF

Abstract

Alzheimer’s disease is a progressive neurodegenerative disorder with limited disease-modifying treatments. This study evaluates the ADMET and drug-likeness properties of Withaferin A using in silico approaches. The compound demonstrated favorable absorption, moderate distribution with blood–brain barrier penetration, and acceptable metabolic stability. However, toxicity predictions such as AMES mutagenicity and hERG inhibition indicate potential safety concerns. The findings support Withaferin A as a promising candidate for further investigation in Alzheimer’s disease.

Keywords:

Withaferin A, Alzheimer’s Disease, ADMET Analysis, Pharmacokinetics, In Silico Study

Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and neuronal loss. Its multifactorial pathogenesis involves amyloid-beta accumulation, tau pathology, oxidative stress, and neuroinflammation. Natural compounds such as Withaferin A from Withania somnifera have gained attention due to their neuroprotective and multi-target pharmacological effects.

Materials and Methods

The study utilized an in silico computational approach using the DeepPK platform for ADMET prediction. The chemical structure of Withaferin A was retrieved from PubChem in SMILES format and analyzed for absorption, distribution, metabolism, excretion, and toxicity parameters relevant to central nervous system targeting.

Results and Discussion

According to the absorption table on page 5, Withaferin A exhibited high intestinal absorption and oral bioavailability, indicating efficient systemic availability. It also showed moderate permeability and acted as a P-glycoprotein inhibitor, potentially improving intracellular retention.

Distribution analysis (page 5–6) indicated blood–brain barrier penetration and moderate plasma protein binding, supporting its suitability for neurological applications. Metabolism studies showed minimal interaction with most CYP enzymes, except CYP3A4 involvement.

Excretion analysis revealed moderate clearance and short half-life, suggesting possible need for optimized dosing strategies. Toxicity predictions (page 7–8) highlighted concerns such as AMES mutagenicity, hERG inhibition, and skin sensitization, indicating potential safety risks despite several safe endpoints.

Conclusion

Withaferin A demonstrates promising pharmacokinetic and drug-likeness properties for Alzheimer’s disease treatment. However, toxicity concerns require further experimental validation. The study highlights the importance of in silico ADMET evaluation in early-stage drug discovery.

References

  1. Abdelnour C. Alzheimer’s disease research.
  2. Das R. Withaferin A pharmacology.
  3. Li B. Drug-likeness models.
  4. Additional references as per original article.